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Abstract 
Extrapulmonary small cell carcinoma of the stomach is a rare and aggressive malignancy 
with a poor prognosis that was first described in 1976 by Matsusaka et al. In 1989 it was 
recognized by the World Health Organization as an independent entity affecting the 
stomach. Pure and composite are the two types of gastric small cell carcinoma reported 
in the literature. We report a case of a 68-year-old African American male with metastatic 
pure-type extrapulmonary small cell cancer of the stomach. The primary lesion measured 
approximately 7 cm in diameter on endoscopy. The diagnosis was made on the basis of 
characteristic histological features of small, round, oval lymphocyte-like cells with 
hyperchromatic nuclei, and scant cytoplasm consistent with small cell carcinoma. Gastric 
small cell carcinoma is typically diagnosed at an advanced stage as demonstrated in our 
case. We conducted a literature review discussing the two types of extrapulmonary small 
cell carcinoma of the stomach and their prevalence. 
Introduction 
Gastric small cell carcinoma (GSCC) is a rare and often fatal malignancy that was first 
described in 1976 by Matsusaka et al. [1]. As of 2008, 107 GSCC cases have been reported 
in the literature [2]. Most reported cases have occurred in Japan, and directly correlate 
with aggressive screening measures for gastric malignancy. GSCC accounts for 0.1% of 
all histologic specimens of gastric tumors [1]. There is usually evidence of metastatic 
disease at diagnosis leading to a poor prognosis. Matsusaka et al. reported two types, 
pure-type and composite-type. Pure-type GSCC is based on histologic specimens in 
which no other tumor types are identified, i.e. adenocarcinoma or squamous cell  
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carcinoma. Composite-type GSCC consists of a mixture of adenocarcinoma and/or 
squamous cell carcinoma along with small cell carcinoma. 
Case Report 
A 68-year-old African American male presented to the gastroenterology practice with lethargy, 
jaundice, unintentional weight loss and abdominal distension. He had no significant past medical or 
family history. Social history was significant for alcohol abuse with consumption of a six pack of beer 
every other day; there was no history of tobacco or recreational drug use.  
Physical examination revealed a cachectic man with bitemporal wasting, dry mucous membranes, 
scleral icterus, abdominal distension consistent with ascites, scrotal and bilateral pitting pedal edema. 
Laboratory tests revealed a hemoglobin of 9.3 g/dl, hematocrit 27%, aspartate aminotransferase (AST) 
314 U/l, alanine aminotransferase (ALT) 211 U/l, alkaline phosphatase (ALP) 1,158 U/l and a total 
bilirubin of 14.8 mg/dl with a direct fraction of 12.1 mg/dl. The patient was admitted to the medical 
floor for intravenous hydration and diagnostic assessment.  
Abdomen ultrasonography was performed and revealed multiple solid-appearing liver lesions 
suspicious for a metastatic process and moderate ascites. Computed tomography (CT) scan of the 
abdomen demonstrated a complex low density lesion measuring 7 × 6 × 5 cm in the right hepatic lobe 
of the liver, cystic masses surrounding the pancreatic head and neck, heterogeneous thickening 
surrounding the gastric fundus, omental caking, and a nodular shrunken liver suggestive of cirrhosis 
(fig. 1). An esophagogastroduodenoscopy (EGD) was performed which revealed a large circumferential 
infiltrating mass of approximately 7 cm in diameter involving the cardia and fundus (fig. 2). Histologic 
examination of the specimens obtained from the gastric mass revealed small, round, oval lymphocyte-
like cells with hyperchromatic nuclei, scant cytoplasm, and frequent mitoses compatible with small cell 
carcinoma (fig. 3). 
Immunohistochemical staining was negative for neuron-specific enolase, synaptophysin, and 
chromogranin A. The patient’s CEA and CA 19-9 level were 2.7 ng/ml and 585 U/ml, respectively. A 
subsequent chest CT did not reveal any significant lung lesions suggestive of a primary small cell lung 
cancer. 
The patient was evaluated by oncology and due to the patient’s advanced tumor stage and 
comorbidities, was deemed a poor candidate for cytotoxic chemotherapy. The patient was placed under 
palliative care. Hospital course was complicated by episodes of hypoglycemia, increasing lethargy, 
change in mental status and large volume hematemesis. The patient subsequently died on day 16 of 
hospitalization.  
Discussion 
Small cell carcinoma is a malignancy frequently observed in the lungs [3], but 
extrapulmonary small cell carcinoma (EPSCC) is rare. EPSCC has been reported from 
the gastrointestinal tract, head and neck, urinary tract and genital organs [2, 4]. Brenner 
et al. reported that most small cell carcinoma of the gastrointestinal tract involved the 
esophagus in 53% of the 544 reported cases. The colon (13%) and the stomach (11%) 
were the second and the third most common sites respectively [5]. 
The incidence of GSCC appears to be underestimated [5]. Based on the literature there 
remains a discrepancy in the actual number of reported cases. Namikawa et al. reported 
107 published cases of GSCC [2]. Tanemura et al. reported 67 cases in Japan alone as of 
2002 [6]. Fukuda et al. reported a patient found to have foci of small cell carcinoma in the 
gastrectomy specimen for well-differentiated tubular adenoma [7]. As stated previously, 
GSCC consists of a pure-type and mixed or composite-type. The composite types 
demonstrate glandular and/or squamous differentiation [8]. We have reviewed the 
classification of a number of GSCC cases reported in the literature and their histological  
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characteristics (table 1). As described in table 1, the number of cases of pure-type and 
composite-type gastric small cell cancer is approximately equivalent.  
Although many theories have been postulated, the origin of small cell carcinoma 
remains unclear. Small cell carcinoma is thought to originate from preexisting 
neuroectodermal cells, pluripotent epithelial stem cells, or adenocarcinoma precursor 
cells. Matsui et al. suggested that these tumors originate from totipotent primitive cells 
which can lead to dual or multiple differentiation, including a mixture of small neoplastic 
cells, squamous cells and adenocarcinomatous cells [8]. The diagnosis is made by 
histologic review of endoscopic or surgical biopsy specimen. 
Cases of histologically proven gastric adenocarcinoma may contain cellular features 
consistent with small call carcinoma. As a result inadequate biopsy sampling may account 
for the underestimation in its incidence. Histology as well as immunohistochemistry are 
considered to be the hallmark of pathological diagnosis. Neuron-specific enolase, 
chromogranin and Grimelius staining are used for immunohistochemical diagnosis [2]. 
Tanemura et al. reported that chromogranin, neuron-specific enolase and Grimelius 
staining were positive in 72.2, 62.2, and 54.2% respectively in the reported cases of gastric 
small cell carcinoma in whom these staining methods were used [6]. In addition, it is 
important to note that in 10–20% of cases of GSCC, immunohistochemical staining for 
the aforementioned tumor markers may yield negative results as demonstrated in our 
patient. Tanemura et al. have suggested that the final diagnosis should be based on 
routine morphologic features seen on light microscopy as immunohistochemistry can be 
negative in some cases [6]. CEA staining can be used to rule out adenocarcinoma [9]. 
CD56 markers can also be used to differentiate between small cell carcinoma and large 
cell carcinoma [13]. 
The natural history of GSCC is comparable to that of pulmonary small cell carcinoma. 
GSCC predominantly occurs in males in their mid sixties [2, 6, 8, 9]. Most of the cases 
were reported from Japan, several cases from Western countries have also been published. 
Presenting symptoms are often identical to gastric adenocarcinoma. Patients present with 
epigastric pain, nausea, anorexia, early satiety, and weight loss [8]. Based on the largest 
reviews of histologically proven GSCC by Namikawa et al. (107 patients) [2] and 
Tanemura et al. (67 patients) [6], these tumors usually occur in the upper-third of the 
stomach. The average tumor size varies from 0.8 to 17 cm as reported by Namikawa et al. 
[2]. Matsui et al. reported an average size ranging from 1 to 11 cm [8]. The mass can be 
polypoid or ulcerating depending upon its size [8, 9]. Since GSCC tumor incidence is low, 
no proper classification for tumor staging or grading has been assigned. There is not a 
well established staging classification for GSCC tumors. GSCC often behaves like 
pulmonary small cell carcinoma, micrometastasis is considered to be present at early 
stages. 
There is no consensus regarding treatment regimens. Since extrapulmonary small cell 
carcinoma is very aggressive, some authors recommend that it be treated similarly to 
pulmonary small cell carcinoma [1–3, 7, 9, 11, 14]. Preoperative chemotherapy has been 
used and is recommended by someone [9, 15]. Intensive chemotherapy in postsurgical 
resection patients has also been recommended [1, 14]. Chemotherapeutic agents 
including cyclophosphamide, doxorubicin and vincristine [3], etoposide/visplatin [4], 
mitomycin, tegafur [8], cisplatin and adriamycin [8, 9] have been tried with varying 
results. Nakamura et al. reported a good response to neoadjuvant chemotherapy with 
carboplatin, epirubicin, etoposide and 5-flurouracil leading to marked reduction in the 
primary tumor and lymph node metastases [15]. Recently, 5-fluorouracil, etoposide and 
lederfolin combination chemotherapy was used in a patient described by Cioppa et al. [1].  
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The same patient received intraarterial hepatic chemotherapy with cisplatin, adriamycin 
and mitomycin-C for the hepatic metastasis [1]. A partial response was described. 
Chemotherapy and radiotherapy should be considered in cases of inoperable GSCC. 
Prognosis is often worse than undifferentiated adenocarcinoma of the stomach. The 
majority of patients with GSCC survive less than one year [2, 8, 9]. 
Conclusion 
Our patient with GSCC is one of the few reported cases in the literature outside of 
Japan. Based on our literature review, we conclude that there is no difference in the 
prevalence of pure type and composite type GSCC. It is important to note that cases of 
composite GSCC may be misdiagnosed as pure type GSCC due to sampling error. The 
location and quantity of specimens obtained from suspicious gastric masses may play a 
role in accurately establishing the diagnosis of GSCC. Further studies need to be 
performed providing guidelines for the evaluation and management of these uncommon 
malignancies. 
 
 
 
Table 1. Review of the literature demonstrating the number of cases of GSCC reported and their 
histological classification into pure and composite types 
Year  Author   Reported  
cases  
Pure  Composite   Not  
determined 
2005  Namikawa et al. [2]  107  41 (38.3%)  44 (41.1%)  22 
2003  Kusayanagi et al. [9]  038  14 (36.8%)  24 (63.1%)  NA 
2002  Tanemura et al. [6]  066  32 (48.4%)  33 (50.0%)  1 
1999  Takaku et al. [10]   032  14 (43.7%)  18 (56.2%)  NA 
1998  Arai and Matsuda [11]   054  24 (44.4%)  30 (55.5%)  NA 
1997  Sato et al. [12]   011  05 (45.4%)  06 (54.5%)  NA 
1991  Matsui et al. [8]  017  05 (29.4%)  12 (70.4%)  NA 
1990  Hussein et al. [3]   008  04 (50.0%)  04 (50.0%)  NA 
1988  Fukuda et al. [7]   004  02 (50.0%)  02 (50.0%)  NA 
NA = Not applicable. 
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Fig. 1. Moderate ascites, heterogenous thickening surrounding the gastric fundus, omental caking, 
nodular shrunken liver consistent with cirrhosis. 
 
 
 
Fig. 2. Endoscopic retroflexed view of the fundal mass. 
 
 
 
Fig. 3. Small, round lymphocyte-like cells with hyperchromatic nuclei, scant cytoplasm and frequent 
mitosis on light microscopy. 
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